Research Analysts Set Expectations for Cerus FY2026 Earnings

Key Points

• Cantor Fitzgerald predicts Cerus Corporation will report a FY2026 earnings per share (EPS) of ($0.10), slightly below the current consensus estimate of ($0.08).
• In its latest quarterly earnings, Cerus reported an EPS of ($0.03), missing the expected ($0.02) by ($0.01), despite revenues of $60.10 million which exceeded expectations.
• Significant increases in share holdings were observed from several hedge funds, with Acadian Asset Management raising its position by 38.6% during the second quarter.

Cerus Corporation (NASDAQ:CERS - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Cerus in a research report issued to clients and investors on Thursday, August 7th. Cantor Fitzgerald analyst R. Osborn forecasts that the biotechnology company will earn ($0.10) per share for the year. The consensus estimate for Cerus' current full-year earnings is ($0.08) per share.

Cerus Trading Down 0.4%

Shares of Cerus stock traded down $0.01 during mid-day trading on Monday, hitting $1.27. The stock had a trading volume of 130,141 shares, compared to its average volume of 1,321,067. The firm has a 50-day moving average of $1.38 and a two-hundred day moving average of $1.44. Cerus has a 12-month low of $1.12 and a 12-month high of $2.39. The company has a quick ratio of 1.35, a current ratio of 2.00 and a debt-to-equity ratio of 1.01. The firm has a market cap of $242.50 million, a P/E ratio of -12.65 and a beta of 1.55.

Cerus (NASDAQ:CERS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biotechnology company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Cerus had a negative net margin of 9.81% and a negative return on equity of 33.77%. The firm had revenue of $60.10 million during the quarter, compared to analysts' expectations of $51.80 million.

Institutional Trading of Cerus

Several hedge funds have recently made changes to their positions in CERS. Merit Financial Group LLC purchased a new position in shares of Cerus during the 1st quarter worth approximately $25,000. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Cerus during the 4th quarter worth approximately $25,000. Focus Partners Advisor Solutions LLC boosted its position in shares of Cerus by 65.2% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 19,930 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 7,866 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Cerus during the 1st quarter worth approximately $32,000. Finally, Dark Forest Capital Management LP acquired a new stake in Cerus during the 4th quarter worth approximately $34,000. Hedge funds and other institutional investors own 78.37% of the company's stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.